WO1998032465A1 - Composition for the transdermal administration of steroid drugs - Google Patents

Composition for the transdermal administration of steroid drugs Download PDF

Info

Publication number
WO1998032465A1
WO1998032465A1 PCT/KR1998/000013 KR9800013W WO9832465A1 WO 1998032465 A1 WO1998032465 A1 WO 1998032465A1 KR 9800013 W KR9800013 W KR 9800013W WO 9832465 A1 WO9832465 A1 WO 9832465A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
drug
diethylene glycol
ranges
absorption promoter
Prior art date
Application number
PCT/KR1998/000013
Other languages
French (fr)
Inventor
Cheol Moon
Je Phil Ryoo
Mi Suk Choi
Jong Kun Choi
Original Assignee
Lg Chemical Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Limited filed Critical Lg Chemical Limited
Priority to AU58820/98A priority Critical patent/AU727811B2/en
Priority to BR9807009-6A priority patent/BR9807009A/en
Priority to EP98902269A priority patent/EP1001812A1/en
Priority to JP10531848A priority patent/JP2000508349A/en
Priority to CA002277970A priority patent/CA2277970A1/en
Publication of WO1998032465A1 publication Critical patent/WO1998032465A1/en
Priority to US09/746,448 priority patent/US20010023261A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Definitions

  • the present invention relates to a composition for the transdermal administration of steroid drugs, wherein a mixture of a diethylene glycol ether and a sorbitan ester is used as an absorption promoter; and to a transdermal formulation containing same.
  • transdermal drug administration alleviates the aforementioned problems and delivers a drug at a controlled rate for an extended period of prescribed time due to increased bioavailability of the drug which is degraded in the digestive tract.
  • Diethyleneglycol monoethyl ether which has been used as a solubilizer in the formulation of naproxen, nitroglycerin, phenylbutazone and prazepa , was also reported to be effective as an absorption promoter in the transdermal administration of theophylline and prostaglandin E2 (Touitou, et al . , International Journal of Pharmaceutics, 20, 159-166(1991); and Watkinson, A. et al . , ibid, 74, 229- 236(1991) ) .
  • absorption promoters disclosed in the prior art include: a mixture of linoleic acid and propyleneglycol (European Patent Publication No. 261429); and mixtures of N- (hydroxyethyl)pyrrolidone and methyl laurate, ethanol and glycerol monolaurate, diethylene glycol monoethyl ether and propyleneglycol monolaurate (US Patent Nos. 4,537,776; 4,764,379; and 4,973,468).
  • the conventional transdermal formulations may be divided into three types: a reservoir type, a simple matrix type and a multi-layer lamination type.
  • the simple matrix type formulation as disclosed in U.S. Patent Nos. 4,314,577; 4,438,139; and 4,839,174, comprises a drug dispersed in a layer made of a pressure-sensitive adhesive matrix.
  • Such formulation can be produced at a low cost by a simple process.
  • it has the problem that the rate of drug release is high in the initial stage and tapers off sharply thereafter.
  • a diethylene glycol monoalkyl ether and a sorbitan ester each of which has been individually known as an absorption promoter having a limited effectiveness, provide a synergistic effect when combined, i.e., a mixture of a diethylene glycol ether and a sorbitan ester has been found to be a remarkably efficient absorption promoter for the transdermal transport of steroid drugs .
  • an object of the present invention to provide an improved composition for the transdermal administration of a steroid drug.
  • composition for the transdermal administration of a steroid drug comprising: a therapeutically effective amount of the drug; an absorption promoter consisting essentially of a diethylene glycol ether and a sorbitan ester; and a pharmaceutically acceptable adhesive matrix.
  • Fig. 1 shows a schematic cross-sectional view of an embodiment of the inventive pharmaceutical formulation for the transdermal delivery of a steroid drug
  • Fig. 2 displays the time-dependent changes in the cumulative amount of estradiol transported across the skin of a hairless mouse as a function of the absorption promoter used;
  • Fig. 3 depicts the time-dependent changes in the cumulative amount of norethisterone acetate transported across the skin of a hairless mouse as a function of the absorption promoter used;
  • Fig. 4 illustrates the time-dependent changes in the cumulative amount of norethisterone acetate transported across human cadaver skin as a function of the absorption promoter used
  • Fig. 5 exhibits the time-dependent changes in the cumulative amount of norethisterone acetate transported across human cadaver skin as a function of the contents of sorbitan monolaurate and diethylene glycol monoethyl ether.
  • the present invention provides a composition for the transdermal administration of a steroid drug, comprising: the steroid drug; a mixture of diethylene glycol ether and sorbitan ester which is used as an absorption promoter; and a pharmaceutically acceptable adhesive matrix.
  • Exemplary steroid drugs for use in the composition of the present invention include estrogens, e.g., estradiol, ethynyl estradiol and estradiol ester; progestogens, e.g., norethisterone, norethisterone acetate, medroxyprogesterone acetate, desogestrel, gestaten and levonorgestrel; androgens, e.g., testosterone, testosterone propionate, testosterone enanthate, testosterone cypionate, methyltestosterone and dihydroepiandrosterone; and a mixture thereof.
  • estrogens e.g., estradiol, ethynyl estradiol and estradiol ester
  • progestogens e.g., norethisterone, norethisterone acetate, medroxyprogesterone acetate, desogestrel, gestaten and levonorgestrel
  • the total amount of the steroid drug used in the inventive composition may range from 0.05 to 30 wt%, preferably, from 0.1 to 10 wt% based on the total weight of the composition.
  • the absorption promoter of the present invention is composed of a diethylene glycol monoalkylether and a sorbitan ester mixed in a weight ratio ranging from 1:4 to 4:1, preferably, from 1:2 to 2:1.
  • Diethyleneglycol monoalkyl ethers which may be suitably used in the present invention include diethylene glycol monoethyl ether and diethylene glycol monomethyl ether, and suitable sorbitan esters include sorbitan monolaurate and sorbitan monooleate.
  • the total amount of the mixture of diethylene glycol ether and sorbitan ester used in the inventive composition may range from 5 to 30 wt%, preferably, from 5 to 25 wt% based on the total weight of the composition, wherein the weight ratio of said two components is kept within the aforementioned range.
  • the pharmaceutically acceptable adhesive matrix used in the present invention may be any of those known in the art, e.g., polyacrylate adhesives such as ethyl-, butyl- and 2- ethylhexyl acrylate, polyisobutylene and silicon rubber.
  • the composition of the present invention may further comprise flavoring agents, preservatives, anti-oxidants, stabilizers and pigments.
  • the transdermal formulation of a steroid drug in accordance with another aspect of the present invention may be constructed using: a protective backing layer which is impermeable to the steroid drug; a drug reservoir layer containing the aforementioned composition of the present invention, one side of which is laminated on the protective backing layer; and a peel layer attached to the other side of the drug reservoir layer, said peel layer being capable of protecting the composition from the environment until it is removed to bring the drug reservoir layer into contact with the skin.
  • the formulation of the present invention may further comprise a supplementary adhesive layer which is selected from those known in the art, e.g., a ring-shaped adhesive layer sealably attached to the periphery of the drug reservoir layer and the protective backing layer.
  • a supplementary adhesive layer which is selected from those known in the art, e.g., a ring-shaped adhesive layer sealably attached to the periphery of the drug reservoir layer and the protective backing layer.
  • Fig. 1 shows a schematic cross-sectional view of an embodiment of the transdermal formulation of the present invention, which comprises peel layer(1), drug reservoir layer(2), protective backing layer(3) and supplementary adhesive layer(4).
  • the inventive composition for the transdermal delivery of a steroid drug has advantages in that: it is a simple matrix-type which can be prepared at a low cost; the use of the improved absorption promoter disclosed above makes it possible to maintain a high flux of the drug for an extended period, the apparent drug permeation rate following zero- order kinetics; and the formation of drug crystals is inhibited even at a high drug loading level owing to the use of said improved absorption promoter.
  • the dosage administered to a patient by using the composition of the present invention can be controlled by adjusting the contents of the drug and the absorption promoter.
  • the flux, or the skin permeation rate (SPR), of a drug through a skin sample was determined by the following procedure.
  • a skin sample either human cadaver skin or a skin piece excised from 6 week-old female hairless mouse, was installed in Valia-Chien diffusion cell(Crown Glass, U.S.A. ) such that the stratum corneum of the skin faced outward from the cell, and then a transdermal formulation containing one or more steroid drugs was fixed on the skin.
  • 3.4 m-2 of physiological saline solution containing 40% of polyethyleneglycol 400 (Sigma Scientific Co.) was added to the cell and stirred for the whole period of experiment.
  • the skin permeation rate (SPR) of the drug through the skin was calculated by regression analysis of the time-dependent cumulative amounts of the drug( ⁇ g/cm 2 /hr) .
  • the mixture thus obtained was poured onto an impermeable protective backing layer (Scotchpak 1109, 3M Co . ) to coat a matrix layer having a thickness of lOOO ⁇ m.
  • the resulting material consisting of the protective backing layer coated with the matrix layer was dried in an oven by raising the temperature stepwise from 60°C to 120°C.
  • the resulting material was cured in open air for 1 hour and a peel layer (Scotchpak 1012, 3M Co.) was laminated thereon.
  • the resulting transdermal formulation was stored at room temperature .
  • Figs . 2 and 3 show the time-dependent cumulative amounts of estradiol and norethisterone acetate transported across the skin as function of absorption promoter used.
  • transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin was employed in place of the mouse skin, and 4 wt% of norethisterone acetate (NETA) was employed together with the absorption promoter listed in Table 2. The results are shown in Table 2 and Fig. 4.
  • NETA norethisterone acetate
  • transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin as well as 0.4 wt% of estradiol and
  • the inventive compositions containing a mixture of diethylene glycol monoethyl ether (TC) and sorbitan monolaurate (SML) having a TC to SML weight ratio in the range of 0.5 to 2 (Examples 1, 2 and 3 ) as the absorption promoter exhibited markedly enhanced permeation rates of the drugs across human cadaver skin, as compared with those observed in Comparative Examples 1-6. The permeation rates follow apparent zero- order kinetics. Further, drug crystals were not observed in Examples 1 , 2 and 3.
  • transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin and 3.5 wt% of testosterone were employed together with the absorption promoters listed Table 4.
  • transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin and 0.8 wt% of estradiol were employed together with the absorption promoters listed Table

Abstract

A composition for the transdermal administration of a steroid drug containing a therapeutically effective amount of the drug; an absorption promoter consisting essentially of a diethylene glycol ether and a sorbitan ester; and a pharmaceutically acceptable adhesive matrix.

Description

COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF STEROID DRUGS
FIELD OF THE INVENTION
The present invention relates to a composition for the transdermal administration of steroid drugs, wherein a mixture of a diethylene glycol ether and a sorbitan ester is used as an absorption promoter; and to a transdermal formulation containing same.
BACKGROUND OF THE INVENTION
The delivery of a drug through skin offers advantages over the conventional oral administration which is hampered by such problems as unpredictable rates of drug absorption, metabolic degradation of the drug and other adverse effects, e.g., gastrointestinal irritation caused by the drug itself or metabolites thereof. Namely, transdermal drug administration alleviates the aforementioned problems and delivers a drug at a controlled rate for an extended period of prescribed time due to increased bioavailability of the drug which is degraded in the digestive tract.
When a drug is transported through the skin, the horny layer of skin acts as a barrier against the permeation of the drug into the systemic circulation. Accordingly, various absorption promoters, or permeation enhancers, which facilitate the drug permeation through the horny layer, have been used in transdermal drug compositions. For example, U.S. Patent Nos. 4,006,218; 3,551,554; 4,568,343; 4,746,515; 4,379,454; 4,906,463; 4,440,777; 4,783,450 and 5,212,199 disclose, as such absorption promoters, dimethyl sulfoxide(DMSO) , dimethylformamide, polyetyleneglycol monolaurate, glycerol monolaurate, ethanol, propyleneglycol monolaurate, eucalyptol, lecithin and sorbitan esters.
Diethyleneglycol monoethyl ether, which has been used as a solubilizer in the formulation of naproxen, nitroglycerin, phenylbutazone and prazepa , was also reported to be effective as an absorption promoter in the transdermal administration of theophylline and prostaglandin E2 (Touitou, et al . , International Journal of Pharmaceutics, 20, 159-166(1991); and Watkinson, A. et al . , ibid, 74, 229- 236(1991) ) .
Other absorption promoters disclosed in the prior art include: a mixture of linoleic acid and propyleneglycol (European Patent Publication No. 261429); and mixtures of N- (hydroxyethyl)pyrrolidone and methyl laurate, ethanol and glycerol monolaurate, diethylene glycol monoethyl ether and propyleneglycol monolaurate (US Patent Nos. 4,537,776; 4,764,379; and 4,973,468).
The conventional transdermal formulations may be divided into three types: a reservoir type, a simple matrix type and a multi-layer lamination type. The simple matrix type formulation, as disclosed in U.S. Patent Nos. 4,314,577; 4,438,139; and 4,839,174, comprises a drug dispersed in a layer made of a pressure-sensitive adhesive matrix. Such formulation can be produced at a low cost by a simple process. However, it has the problem that the rate of drug release is high in the initial stage and tapers off sharply thereafter.
Further, there exist needs to deliver a large dose of a drug over an extended period using a simple matrix-type formulation. For this purpose, there have been attempts to raise the drug content of the matrix to a level beyond the solubility of the drug in the matrix, i.e., supersaturate the matrix with the drug. However, supersaturation represents a thermodynamically unstable state and the drug in such formulation tends to form crystals . To alleviate this problem, crystal formation inhibitors, e.g., polyvinylpyrrolidone and polyvinylpyrrolidone-vinylacetate copolymer, have been used but the effectiveness thereof was observed to be marginal (Ma, X. et al . , ibid, 142 , 115- 119(1996)) .
Accordingly, there exists a need for an improved matrix-type transdermal formulation of drugs having a steady and high rate of drug release over an extended period and also a high level of uncrystallized drug content. The present inventors have endeavored to develop an improved composition for the transdermal administration of steroid drugs, the composition having a new absorption promoter which is capable of fulfilling the above needs. It has been unexpectedly found that a diethylene glycol monoalkyl ether and a sorbitan ester, each of which has been individually known as an absorption promoter having a limited effectiveness, provide a synergistic effect when combined, i.e., a mixture of a diethylene glycol ether and a sorbitan ester has been found to be a remarkably efficient absorption promoter for the transdermal transport of steroid drugs .
SUMMARY OF THE INVENTION
It is, therefore, an object of the present invention to provide an improved composition for the transdermal administration of a steroid drug.
It is another object of the present invention to provide a transdermal formulation comprising said composition.
In accordance with one aspect of the present invention, there is provided a composition for the transdermal administration of a steroid drug, comprising: a therapeutically effective amount of the drug; an absorption promoter consisting essentially of a diethylene glycol ether and a sorbitan ester; and a pharmaceutically acceptable adhesive matrix.
BRIEF DESCRIPTION OF DRAWINGS
The above and other objects and features of the present invention will become apparent from the following description of the invention taken in conjunction with the following accompanying drawings, wherein: Fig. 1 shows a schematic cross-sectional view of an embodiment of the inventive pharmaceutical formulation for the transdermal delivery of a steroid drug;
Fig. 2 displays the time-dependent changes in the cumulative amount of estradiol transported across the skin of a hairless mouse as a function of the absorption promoter used;
Fig. 3 depicts the time-dependent changes in the cumulative amount of norethisterone acetate transported across the skin of a hairless mouse as a function of the absorption promoter used;
Fig. 4 illustrates the time-dependent changes in the cumulative amount of norethisterone acetate transported across human cadaver skin as a function of the absorption promoter used; and
Fig. 5 exhibits the time-dependent changes in the cumulative amount of norethisterone acetate transported across human cadaver skin as a function of the contents of sorbitan monolaurate and diethylene glycol monoethyl ether.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a composition for the transdermal administration of a steroid drug, comprising: the steroid drug; a mixture of diethylene glycol ether and sorbitan ester which is used as an absorption promoter; and a pharmaceutically acceptable adhesive matrix.
Exemplary steroid drugs for use in the composition of the present invention include estrogens, e.g., estradiol, ethynyl estradiol and estradiol ester; progestogens, e.g., norethisterone, norethisterone acetate, medroxyprogesterone acetate, desogestrel, gestaten and levonorgestrel; androgens, e.g., testosterone, testosterone propionate, testosterone enanthate, testosterone cypionate, methyltestosterone and dihydroepiandrosterone; and a mixture thereof.
The total amount of the steroid drug used in the inventive composition may range from 0.05 to 30 wt%, preferably, from 0.1 to 10 wt% based on the total weight of the composition.
The absorption promoter of the present invention is composed of a diethylene glycol monoalkylether and a sorbitan ester mixed in a weight ratio ranging from 1:4 to 4:1, preferably, from 1:2 to 2:1. Diethyleneglycol monoalkyl ethers which may be suitably used in the present invention include diethylene glycol monoethyl ether and diethylene glycol monomethyl ether, and suitable sorbitan esters include sorbitan monolaurate and sorbitan monooleate.
The total amount of the mixture of diethylene glycol ether and sorbitan ester used in the inventive composition may range from 5 to 30 wt%, preferably, from 5 to 25 wt% based on the total weight of the composition, wherein the weight ratio of said two components is kept within the aforementioned range.
The pharmaceutically acceptable adhesive matrix used in the present invention may be any of those known in the art, e.g., polyacrylate adhesives such as ethyl-, butyl- and 2- ethylhexyl acrylate, polyisobutylene and silicon rubber.
The composition of the present invention may further comprise flavoring agents, preservatives, anti-oxidants, stabilizers and pigments. The transdermal formulation of a steroid drug in accordance with another aspect of the present invention may be constructed using: a protective backing layer which is impermeable to the steroid drug; a drug reservoir layer containing the aforementioned composition of the present invention, one side of which is laminated on the protective backing layer; and a peel layer attached to the other side of the drug reservoir layer, said peel layer being capable of protecting the composition from the environment until it is removed to bring the drug reservoir layer into contact with the skin.
The formulation of the present invention may further comprise a supplementary adhesive layer which is selected from those known in the art, e.g., a ring-shaped adhesive layer sealably attached to the periphery of the drug reservoir layer and the protective backing layer.
Fig. 1 shows a schematic cross-sectional view of an embodiment of the transdermal formulation of the present invention, which comprises peel layer(1), drug reservoir layer(2), protective backing layer(3) and supplementary adhesive layer(4).
The inventive composition for the transdermal delivery of a steroid drug has advantages in that: it is a simple matrix-type which can be prepared at a low cost; the use of the improved absorption promoter disclosed above makes it possible to maintain a high flux of the drug for an extended period, the apparent drug permeation rate following zero- order kinetics; and the formation of drug crystals is inhibited even at a high drug loading level owing to the use of said improved absorption promoter. The dosage administered to a patient by using the composition of the present invention can be controlled by adjusting the contents of the drug and the absorption promoter.
The following Examples are intended to further illustrate the present invention without limiting its scope.
Determination of Drug Permeation Rate through Skin
The flux, or the skin permeation rate (SPR), of a drug through a skin sample was determined by the following procedure. A skin sample, either human cadaver skin or a skin piece excised from 6 week-old female hairless mouse, was installed in Valia-Chien diffusion cell(Crown Glass, U.S.A. ) such that the stratum corneum of the skin faced outward from the cell, and then a transdermal formulation containing one or more steroid drugs was fixed on the skin. 3.4 m-2 of physiological saline solution containing 40% of polyethyleneglycol 400 (Sigma Scientific Co.) was added to the cell and stirred for the whole period of experiment. Thereafter, lOOμl samples of the physiological saline solution were taken periodically and subjected to high performance liquid chromatography to determine the cumulative amount of the drug transported across the skin. The skin permeation rate (SPR) of the drug through the skin was calculated by regression analysis of the time-dependent cumulative amounts of the drug(μg/cm2/hr) .
The process described above was repeated 3 times and averaged to define SPR of the drug.
Reference Example 1 : Preparation and Testing of
Transdermal Administration
Compositions containing Conventional Absorption Promoters
(hairless mouse skin)
0.6 wt% of estradiol (ED) , 3.0 wt% of norethisterone acetate (NETA) and an absorption promoter listed in Table 1 were added to a polyacrylate adhesive (Durotac 87-2074, National Starch Chem. Co.), and then the mixture was stirred sufficiently to dissolve the drugs in the adhesive.
The mixture thus obtained was poured onto an impermeable protective backing layer (Scotchpak 1109, 3M Co . ) to coat a matrix layer having a thickness of lOOOμm. The resulting material consisting of the protective backing layer coated with the matrix layer was dried in an oven by raising the temperature stepwise from 60°C to 120°C. The resulting material was cured in open air for 1 hour and a peel layer (Scotchpak 1012, 3M Co.) was laminated thereon. The resulting transdermal formulation was stored at room temperature .
The permeation rates of the drugs across the skin of hairless mouse were determined and the results are shown in Table 1 and Figs. 2 and 3. Table 1 Permeation rates of ED and NETA across mouse skin in the presence of conventional absorption promoter
Figure imgf000010_0001
*SPR: Skin permeation rate across the skin (mean±SD(μg/cm2/hr) )
Figs . 2 and 3 show the time-dependent cumulative amounts of estradiol and norethisterone acetate transported across the skin as function of absorption promoter used.
As can be seen from Table 1 and Figs . 2 and 3 , the compositions containing sorbitan monolaurate(Reference Example 1-4) and squalene (Reference Example 1-5) as the absorption promoter exhibited high permeation rates . However, crystals of the drugs were observed in each of the above Reference Examples . Reference Example 2 Preparation and Testing of Transdermal Administration
Compositions containing
Conventional Absorption Promoters (human cadaver skin)
Four transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin was employed in place of the mouse skin, and 4 wt% of norethisterone acetate (NETA) was employed together with the absorption promoter listed in Table 2. The results are shown in Table 2 and Fig. 4.
Table 2. Permeation rates of NETA across human cadaver skin when conventional absorption promoters are used
Figure imgf000011_0001
As can be seen from Table 2 and Fig. 4, the compositions containing sorbitan monolaurate (Reference Example 2-2), squalene (Reference Example 2-3) and diethylene glycol monoethyl ether (Reference Example 2-4) as the absorption promoter enhanced the permeation rate of NETA across human cadaver skin to an extent that is significantly lower than that determined for the hairless mouse skin. Further, drug crystal formation was observed in all but Reference Example 2-4, wherein diethylene glycol monoethyl ether was employed as the absorption promoter. Example 1 to 3 and Comparative Examples 1 to 6 :
Nine transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin as well as 0.4 wt% of estradiol and
2.7 wt% of norethisterone acetate were employed together with the absorption promoters listed in Table 3.
As a positive control, a commercially available reservoir type formulation, i.e., Estragestβ(EG, CibaGeigy, Swiss) was used in Comparative Example 6. The results are shown in Table 3 and Fig. 5.
Table 3. Permeation rates of ED and NETA across human cadaver skin
Figure imgf000013_0001
SML: sorbitan monolaurate,
TC: diethylene glycol monoethyl ether
As can be seen from Table 3 and Fig. 5, the inventive compositions containing a mixture of diethylene glycol monoethyl ether (TC) and sorbitan monolaurate (SML) having a TC to SML weight ratio in the range of 0.5 to 2 (Examples 1, 2 and 3 ) as the absorption promoter exhibited markedly enhanced permeation rates of the drugs across human cadaver skin, as compared with those observed in Comparative Examples 1-6. The permeation rates follow apparent zero- order kinetics. Further, drug crystals were not observed in Examples 1 , 2 and 3.
Example 4 and Comparative Examples 7 to 10:
Five transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin and 3.5 wt% of testosterone were employed together with the absorption promoters listed Table 4.
Table 4. Permeation rates of testosterone across human cadaver skin
Figure imgf000014_0001
As the results in Table 4 show, the inventive composition containing a mixture of diethylene glycol monoethyl ether(TC) and sorbitan monolaurate( SML) (Example 4 ) as the absorption promoter exhibited a markedly higher permeation rate than those observed when TC or SML was used alone (Comparative Examples 8 and 9). Examples 5 to 7 and Comparative Examples 11 to 12:
Five transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin and 0.8 wt% of estradiol were employed together with the absorption promoters listed Table
5.
Table 5. Permeation rates of estradiol across human cadaver skin as a function of the absorption promoter used
Figure imgf000015_0001
As the results in Table 5 show, the inventive compositions containing a mixture of diethylene glycol monoethyl ether (TC) and sorbitan monolaurate (SML) having a TC to SML ratio ranging from 1 to 4 (Example Nos. 5, 6 and 7) exhibited enhanced permeation rates estradiol through human cadaver skin.

Claims

What is claimed is:
1. A composition for the transdermal administration of a steroid drug, comprising: a therapeutically effective amount of the drug; an absorption promoter consisting essentially of a diethylene glycol ether and a sorbitan ester; and a pharmaceutically acceptable adhesive matrix.
2. The composition of claim 1, wherein the weight ratio of the diethylene glycol ether and the sorbitan ester ranges from 1:4 to 4:1.
3. The composition of claim 2, wherein the weight ratio of the diethylene glycol ether and the sorbitan ester ranges from 1:2 to 2:1.
4. The composition of claim 1, wherein the diethylene glycol ether is diethylene glycol monoethyl ether, diethylene glycol monomethyl ether or a mixture thereof.
5. The composition of claim 1, wherein the sorbitan ester is sorbitan monolaurate, sorbitan monooleate or a mixture thereof.
6. The composition of claim 1, wherein the steroid drug is an estrogen, progestogen, androgen or a mixture thereof .
7. The composition of claim 6, wherein the estrogen is estradiol, ethynyl estradiol or estradiol ester.
8. The composition of claim 6, wherein the progestogen is norethisterone, norethisterone acetate, medroxyprogesterone acetate, desogestrel, gestaten or levonorgestrel .
9. The composition of claim 6, wherein the androgen is testosterone, testosterone propionate, testosterone enanthate, testosterone cypionate, methyltestosterone or dehydroepiandrosterone .
10. The composition of claim 1, wherein the amount of the steroid drug ranges from 0.05 to 30 wt% based on the total weight of the composition.
11. The composition of claim 10, wherein the amount of the steroid drug ranges from 0.1 to 10 wt% based on the total weight of the composition.
12. The composition of claim 1, wherein the amount of the absorption promoter ranges from 5 to 30 wt% based on the total weight of the composition.
13. The composition of claim 12, wherein the amount of the absorption promoter ranges from 5 to 25 wt% based on the total weight of the composition.
14. The composition of claim 1, wherein the adhesive matrix is a polyacrylate adhesive, polyisobutylene or silicon rubber.
15. A transdermal formulation for the transdermal administration of a steroid drug, comprising: a protective backing layer; a drug reservoir layer containing the composition of claim 1, which is placed on the protective backing layer, one side of which is laminated on the protective backing layer; and a removable peel layer attached to the other side of the drug reservoir layer.
16. The formulation of claim 15, which further comprises a supplementary adhesive layer.
PCT/KR1998/000013 1997-01-27 1998-01-23 Composition for the transdermal administration of steroid drugs WO1998032465A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU58820/98A AU727811B2 (en) 1997-01-27 1998-01-23 Composition for the transdermal administration of steroid drugs
BR9807009-6A BR9807009A (en) 1997-01-27 1998-01-23 Composition for administration of steroid drug transfer
EP98902269A EP1001812A1 (en) 1997-01-27 1998-01-23 Composition for the transdermal administration of steroid drugs
JP10531848A JP2000508349A (en) 1997-01-27 1998-01-23 Composition for transdermal administration of steroid drug
CA002277970A CA2277970A1 (en) 1997-01-27 1998-01-23 Composition for the transdermal administration of steroid drugs
US09/746,448 US20010023261A1 (en) 1997-01-27 2000-12-12 Novel composition for the transdermal administration of drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019970002233A KR100215027B1 (en) 1997-01-27 1997-01-27 Composition for transdermal administration of steroid drugs and formulation containing same
KR1997/2233 1997-01-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US29325599A Continuation-In-Part 1997-01-27 1999-04-16

Publications (1)

Publication Number Publication Date
WO1998032465A1 true WO1998032465A1 (en) 1998-07-30

Family

ID=19495561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1998/000013 WO1998032465A1 (en) 1997-01-27 1998-01-23 Composition for the transdermal administration of steroid drugs

Country Status (12)

Country Link
EP (1) EP1001812A1 (en)
JP (1) JP2000508349A (en)
KR (1) KR100215027B1 (en)
CN (1) CN1244806A (en)
AR (1) AR011577A1 (en)
AU (1) AU727811B2 (en)
BR (1) BR9807009A (en)
CA (1) CA2277970A1 (en)
ID (1) ID19755A (en)
RU (1) RU2176499C2 (en)
TW (1) TW537899B (en)
WO (1) WO1998032465A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062557A1 (en) * 1998-06-02 1999-12-09 Lg Chemical Limited Composition for the transdermal administration of non-steroidal anti-inflammatory drugs
WO2000040230A2 (en) * 1999-01-06 2000-07-13 Cedars-Sinai Medical Center Hormone replacement for breast cancer patients
WO2002066018A2 (en) * 2001-02-19 2002-08-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing testosterone and method for the production thereof
FR2848112A1 (en) * 2002-12-10 2004-06-11 Besins Int Belgique PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY COMPRISING AT LEAST ONE PROGESTATIVE AND / OR AT LEAST ONE OESTROGEN, PREPARATION METHOD AND USES THEREOF
WO2004054544A1 (en) * 2002-12-10 2004-07-01 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration comprising a progestin or an estrogen, method for preparing same and uses thereof
WO2006061340A2 (en) * 2004-12-10 2006-06-15 Grünenthal GmbH Stable, hormone-containing (intermediate) product
US7611727B2 (en) 2003-02-20 2009-11-03 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100403051B1 (en) * 2000-07-25 2003-10-23 일양약품주식회사 Composition of matrix type patch for transdermal testosterone delivery and process for preparing the same
JP4422430B2 (en) * 2003-05-14 2010-02-24 帝國製薬株式会社 External patch containing estrogen and / or progestogen
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
CN1313084C (en) * 2004-11-05 2007-05-02 郑会义 Percutaneous contraceptive drugs delivery system and method
JP4969050B2 (en) * 2005-01-07 2012-07-04 ロート製薬株式会社 Topical skin preparation
JP2007045808A (en) * 2005-01-07 2007-02-22 Rohto Pharmaceut Co Ltd Skin care preparation
WO2013054809A1 (en) * 2011-10-14 2013-04-18 大正製薬株式会社 External preparation for skin
JP5521025B2 (en) * 2012-12-21 2014-06-11 日本精化株式会社 Penetration enhancer
KR101968873B1 (en) * 2018-09-21 2019-04-29 아이큐어 주식회사 Cosmetic composition comprising peptide derived from Botulinum toxin having improved cell penetrating ability

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321252A (en) * 1979-08-14 1982-03-23 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing ester derivatives of estradiol
EP0275550A1 (en) * 1986-12-24 1988-07-27 Teikoku Seiyaku Kabushiki Kaisha Adhesive device for application to body tissue
EP0285563A1 (en) * 1987-04-02 1988-10-05 Ciba-Geigy Ag Transdermal therapeutic systems for combinations of active agents
EP0322098A1 (en) * 1987-11-25 1989-06-28 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesives and bioelectrodes constructed with the adhesive
EP0328806A2 (en) * 1988-02-16 1989-08-23 Paco Pharmaceutical Services Estradiol transdermal delivery system
WO1990011064A1 (en) * 1989-03-22 1990-10-04 Cygnus Research Corporation Skin permeation enhancer compositions
EP0399432A2 (en) * 1989-05-25 1990-11-28 Takeda Chemical Industries, Ltd. Transdermal therapeutic composition
WO1993023083A1 (en) * 1992-05-11 1993-11-25 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
EP0573133A1 (en) * 1988-10-27 1993-12-08 Schering Aktiengesellschaft Means for transdermal application of Gestoden

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321252A (en) * 1979-08-14 1982-03-23 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing ester derivatives of estradiol
EP0275550A1 (en) * 1986-12-24 1988-07-27 Teikoku Seiyaku Kabushiki Kaisha Adhesive device for application to body tissue
EP0285563A1 (en) * 1987-04-02 1988-10-05 Ciba-Geigy Ag Transdermal therapeutic systems for combinations of active agents
EP0322098A1 (en) * 1987-11-25 1989-06-28 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesives and bioelectrodes constructed with the adhesive
EP0328806A2 (en) * 1988-02-16 1989-08-23 Paco Pharmaceutical Services Estradiol transdermal delivery system
EP0573133A1 (en) * 1988-10-27 1993-12-08 Schering Aktiengesellschaft Means for transdermal application of Gestoden
WO1990011064A1 (en) * 1989-03-22 1990-10-04 Cygnus Research Corporation Skin permeation enhancer compositions
EP0399432A2 (en) * 1989-05-25 1990-11-28 Takeda Chemical Industries, Ltd. Transdermal therapeutic composition
WO1993023083A1 (en) * 1992-05-11 1993-11-25 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062557A1 (en) * 1998-06-02 1999-12-09 Lg Chemical Limited Composition for the transdermal administration of non-steroidal anti-inflammatory drugs
WO2000040230A2 (en) * 1999-01-06 2000-07-13 Cedars-Sinai Medical Center Hormone replacement for breast cancer patients
WO2000040230A3 (en) * 1999-01-06 2001-05-17 Cedars Sinai Medical Center Hormone replacement for breast cancer patients
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9132089B2 (en) 2000-08-30 2015-09-15 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
KR100787545B1 (en) * 2001-02-19 2007-12-21 엘티에스 로만 테라피-시스템 악티엔게젤샤프트 Transdermal preparation form containing testosterone and method for the production thereof
WO2002066018A2 (en) * 2001-02-19 2002-08-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing testosterone and method for the production thereof
WO2002066018A3 (en) * 2001-02-19 2003-04-24 Lohmann Therapie Syst Lts Transdermal therapeutic system containing testosterone and method for the production thereof
AU2002247690B2 (en) * 2001-02-19 2006-06-22 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing testosterone and method for the production thereof
WO2004054544A1 (en) * 2002-12-10 2004-07-01 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration comprising a progestin or an estrogen, method for preparing same and uses thereof
FR2848112A1 (en) * 2002-12-10 2004-06-11 Besins Int Belgique PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY COMPRISING AT LEAST ONE PROGESTATIVE AND / OR AT LEAST ONE OESTROGEN, PREPARATION METHOD AND USES THEREOF
US7611727B2 (en) 2003-02-20 2009-11-03 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration
WO2006061340A3 (en) * 2004-12-10 2006-08-24 Gruenenthal Gmbh Stable, hormone-containing (intermediate) product
WO2006061340A2 (en) * 2004-12-10 2006-06-15 Grünenthal GmbH Stable, hormone-containing (intermediate) product
US11040043B2 (en) 2009-10-27 2021-06-22 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US11793819B2 (en) 2011-11-23 2023-10-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11103516B2 (en) 2011-11-23 2021-08-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8846649B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8846648B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10675288B2 (en) 2011-11-23 2020-06-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9248136B2 (en) 2011-11-23 2016-02-02 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11033626B2 (en) 2012-06-18 2021-06-15 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10639375B2 (en) 2012-06-18 2020-05-05 Therapeuticsmd, Inc. Progesterone formulations
US11865179B2 (en) 2012-06-18 2024-01-09 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11529360B2 (en) 2012-06-18 2022-12-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11166963B2 (en) 2012-06-18 2021-11-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11110099B2 (en) 2012-06-18 2021-09-07 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987238B2 (en) 2012-06-18 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9006222B2 (en) 2012-06-18 2015-04-14 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9012434B2 (en) 2012-06-18 2015-04-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11304959B2 (en) 2012-12-21 2022-04-19 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10835487B2 (en) 2012-12-21 2020-11-17 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10888516B2 (en) 2012-12-21 2021-01-12 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11351182B2 (en) 2012-12-21 2022-06-07 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11241445B2 (en) 2012-12-21 2022-02-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11065197B2 (en) 2012-12-21 2021-07-20 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11497709B2 (en) 2012-12-21 2022-11-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11622933B2 (en) 2012-12-21 2023-04-11 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11116717B2 (en) 2012-12-21 2021-09-14 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11123283B2 (en) 2012-12-21 2021-09-21 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11103513B2 (en) 2014-05-22 2021-08-31 TherapeuticsMD Natural combination hormone replacement formulations and therapies
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10398708B2 (en) 2014-10-22 2019-09-03 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10668082B2 (en) 2014-10-22 2020-06-02 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10912783B2 (en) 2015-07-23 2021-02-09 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10532059B2 (en) 2016-04-01 2020-01-14 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Also Published As

Publication number Publication date
JP2000508349A (en) 2000-07-04
BR9807009A (en) 2000-03-14
AU727811B2 (en) 2000-12-21
TW537899B (en) 2003-06-21
CA2277970A1 (en) 1998-07-30
KR19980066583A (en) 1998-10-15
CN1244806A (en) 2000-02-16
EP1001812A1 (en) 2000-05-24
RU2176499C2 (en) 2001-12-10
ID19755A (en) 1998-07-30
AU5882098A (en) 1998-08-18
KR100215027B1 (en) 1999-08-16
AR011577A1 (en) 2000-08-30

Similar Documents

Publication Publication Date Title
AU727811B2 (en) Composition for the transdermal administration of steroid drugs
US20010023261A1 (en) Novel composition for the transdermal administration of drugs
US9005653B2 (en) Transdermal delivery of hormones with low concentration of penetration enhancers
CA2183543C (en) Sexual steroid-containing transdermal therapeutic systems
JPH09501398A (en) Active ingredient patch
KR20050044628A (en) Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate
SK280493B6 (en) Self-adhesive plasters for transdermal application of system-like acting steroidal hormones and process for preparing thereof
IL176112A (en) Composition for transdermal delivery containing gestodene and a carrier, a transdermal therapeutic system comprising gestodene and a kit
EP1541137B1 (en) Transdermal delivery system of gestodene
WO1999062557A1 (en) Composition for the transdermal administration of non-steroidal anti-inflammatory drugs
JPH09508911A (en) Transdermal preparation containing desogestrel
MXPA99006959A (en) Composition for the transdermal administration of steroid drugs
KR960013236B1 (en) Transdermal estrogen / progestin delivering device and a kit having the same
US8671945B2 (en) Low-dose transdermal patches with high drug release

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98802010.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP MX RU SG US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 58820/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2277970

Country of ref document: CA

Ref document number: 2277970

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998902269

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1998 531848

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/006959

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1998902269

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 58820/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998902269

Country of ref document: EP